Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis:

Multiple Sclerosis Journal – Experimental, Translational and Clinical

Gill Webster¹  Michael H Silverman²  Tim Anderson³  Alison M Luckey³ 

[1] BioStrategics Consulting Ltd, Marblehead, MA, USA;New Zealand Brain Research Institute, Christchurch, New Zealand;Primorus Clinical Trials Ltd, Christchurch, New Zealand

关键词: Multiple sclerosis;    MIS416;    immune modulator;    myeloid cells;    safety;    pharmacodynamic;    pattern recognition receptor;    PRR;    NOD-2;    TLR-9;   

DOI  :  10.1177/2055217315583385

学科分类：医学（综合）

来源: Sage Journals

【 授权许可】

CC BY-NC